diagnosis of primary invasive non-metastatic breast cancer, stages I-III
female based on biological sex
40 to 80 years of age
completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation
absence of contraindications to exercise or study participation
study clinician approval
receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation
lymphedema stage ≥ 2 prior to study enrolment
any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months
